Israeli-based Teva Pharmaceutical Industries has succeeded in acquiring German generic drug maker Ratiopharm for $4.9 billion, beating out U.S. drug firms Pfizer and Actavis of Iceland in the bidding that ended Friday.
Ratiopharm, owned by the Merckle family, posts an average $8.6 billion in sales annually and is tied with Stada for second place as Germany’s generic medication manufacturer.
Ratiopharm, owned by the Merckle family, posts an average $8.6 billion in sales annually and is tied with Stada for second place as Germany’s generic medication manufacturer.
Read more